Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients

Sponsor
University of Aarhus
Study ID
NCT01664676
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
20 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans. This study will investigate the short-term effect of liraglutide (GLP-1 analogue) on the kidneys in type 2 diabetic patients. Impact on basic kidney physiological will be determined and kidney injury markers will be measured as surrogate parameters of kidney protection.

Key Dates

Start date
Dec 31, 2012
Status verified
Feb 2014
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014

Study Design

Enrollment
11 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    1.2 mg liraglutide sc. (single-dose)
  • Placebo Comparator: Placebo-liraglutide
    Placebo liraglutide sc. (single-dose)

Primary Outcome Measure

Glomerular Filtration Rate (51Cr-EDTA plasma clearance) [ Time Frame: 10-15 hours post-dose ]

Related Studies